(Q30795793)

English

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Mills

1

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

G Crofoot

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

R Ortiz

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

B Rashbaum

4

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

W Towner

5

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

D Ward

6

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

C Brinson

7

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

R Kulkarni

8

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

W Garner

9

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

R Ebrahimi

10

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

H Cao

11

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

A Cheng

12

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

J Szwarcberg

13

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

51-56

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1310%2FHCT1502-51

21 January 2018

Identifiers

10.1310/HCT1502-51

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30795793&oldid=1956781633"